205 related articles for article (PubMed ID: 11014576)
1. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
[TBL] [Abstract][Full Text] [Related]
2. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
3. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer.
Miyoshi T; Kondo K; Hino N; Uyama T; Monden Y
Clin Cancer Res; 1997 Aug; 3(8):1289-97. PubMed ID: 9815811
[TBL] [Abstract][Full Text] [Related]
4. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
7. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
Saegusa M; Machida D; Hashimura M; Okayasu I
J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
[TBL] [Abstract][Full Text] [Related]
8. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 in primary lung carcinomas using histological and cytological analyses.
Shimbori M; Kijima H; Sato S; Yoshida H; Sato T; Terasaki-Fukuzawa Y; Onoda N; Kanabuchi K; Abe Y; Nakamura M; Hattori M; Ohno E; Kuramoto H
Anticancer Res; 2003; 23(1A):115-21. PubMed ID: 12680202
[TBL] [Abstract][Full Text] [Related]
10. CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma.
Lee LN; Kuo SH; Lee YC; Chang YL; Chang HC; Jan IS; Yang PC
J Formos Med Assoc; 2005 Aug; 104(8):541-8. PubMed ID: 16193174
[TBL] [Abstract][Full Text] [Related]
11. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor.
Chen TF; Jiang GL; Fu XL; Wang LJ; Qian H; Wu KL; Zhao S
Lung Cancer; 2007 Apr; 56(1):105-14. PubMed ID: 17166620
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3.
Kuniyasu H; Oue N; Tsutsumi M; Tahara E; Yasui W
Clin Cancer Res; 2001 Dec; 7(12):4067-72. PubMed ID: 11751503
[TBL] [Abstract][Full Text] [Related]
13. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
17. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance.
Hayashi M; Tokuchi Y; Hashimoto T; Hayashi S; Nishida K; Ishikawa Y; Nakagawa K; Tsuchiya S; Okumura S; Tsuchiya E
Anticancer Res; 2001; 21(1B):535-40. PubMed ID: 11299800
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
[TBL] [Abstract][Full Text] [Related]
19. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx.
Rodrigo JP; Domínguez F; Alvarez C; González MV; Herrero A; Suárez C
Am J Clin Pathol; 2002 Jul; 118(1):67-72. PubMed ID: 12109858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
